4:18PM Exelixis beats by $0.05, beats on revs (EXEL) 4.59 -0.05 : Reports Q1 (Mar) loss of $0.24 per share, $0.05 better than the Capital IQ Consensus Estimate of ($0.29); revenues fell 47.6% year/year to $9.7 mln vs the $5.33 mln consensus.
Although what we all want to see is great news at ASCO and beyond.
Clem, this is the most manipulated stock I have ever played long term...
Everyone "disses" this bad boy, so any street-beat is a win.
I'm with you...this play is all about ASCO & beyond...
I didn't see any bad news today, and the stock actually traded down into the $4.30's in AH...
Shorts are covering, if only 10% in 4 months. Who do they think they are fooling?
Buffalo Springfield ,wilderguide ,double entendre.Viking horns and a beer;hey? I was born at the Mayo Clinic Hospital and raised in Rochester,So I'm a big Vikings aficionado, and fan. I may have another beer now myself, as the Cabo wait goes on. Ciao!